Venture Funding Deals, July – August 2016
Executive Summary
Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.
You may also be interested in...
Elgan Hopes Perseverance With Enteral Insulin For Preterm Infants Will Pay Off
The product improved GI function and reduced related complications, including life-threatening events, in a Phase III study despite an initial futility analysis. An exec stayed confident, acquired the product and plans to initiate a confirmatory trial.
Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
Clinical Data And Cash: Inflammation Focused InflaRx Hots Up
Positive Phase II data in sepsis and a €31m private financing round: 2016 has been a busy year for inflammation focused German biotech InflaRx.